A study to demonstrate the equivalence in efficacy and safety of once-daily nisoldipine CC and amlodipine in the treatment of mild to moderate hypertension

Acta Therapeutica

Volumn 22, Issue 1, 1996, Pages 23-35

  Marazzi, P ^a,b  

^a Medical Centre   (United Kingdom)

^b Medical Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL BLOCKING AGENT; NISOLDIPINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ESSENTIAL HYPERTENSION; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VERTIGO;

EID: 0029926906     PISSN: 03780619     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. OPIE, L.H - In : Clinical use of calcium channel antagonist drugs. Kluwer Academic Publishers, Boston, part V, pp. 219-244 (1990).
2. LEWIS, B.S. Efficacy and safety of nisoldipine coat-core in the management of angina pectoris, systemic hypertension, and ischaemic ventricular dysfunction. American Journal of Cardiology, 75: 46E (1995).
3. ZANNAD, F. Clinical pharmacology of nisoldipine coat-core. American Journal of Cardiology, 75: 41E (1995).
4. VAN HARTEN, J., VAN BRUMMELEN, P., ZEEGERS, R.R.E.C.M., DARHOFF, M., BREIMER, D.D. The influence of infusion rate on the pharmacokinetics and haemodynamic effects of nisoldipine in man. British Journal of Clinical Pharmacology, 25: 709 (1988).
5. GRAEFE, K.H., ZIEGLER, R., WINGENDER, W., RÂMSCH, K.D., AHR, G. Cardiovascular effects of dihydropyridine calcium-channel antagonists and their relation to drug levels in plasma. Annals of the New York Academy of Sciences, 522: 628 (1988).
6. KAZDA, S., GARTHOFF, B., MEYER, H., SCHLOSSMANN, K., STOEPEL, K., TOWART, R., VATER, W., WEHINGER, E. Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3-5-pyridine-carboxylate (nisoldipine, Bay k 5552). Arzneimittel-Forschung, 30: 2144 (1980).
7. FRIEDEL, H.A., SORKIN, E.M. Nisoldipine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs, 36: 682 (1988).
8. CLAVIJO, G.A., DE CLAVIO, I.V., WEART, C.W. Amlodipine: a new calcium antagonist. American Journal of Hospital Pharmacy, 51: 59 (1994).
9. FRICK, M.H., MCGIBNEY, D., TYLER, H.M. A dose-response study of amlodipine in mild to moderate hypertension. Journal of Internal Medicine, 225: 101-105 (1989).
10. OPIE, L.H., MYBURGH, D.P., ROSNDORFF, C., SARELI, P., SEEDAT, Y.K., MÜLLER, F.O., WEICH, D.J.V. The efficacy and tolerability of nisoldipine in a controlled-release formulation, versus placebo, in the treatment of essential hypertension. Submitted to Am. J. Hypertension.
11. ZANCHETTI, A. Role of calcium antagonists in systemic hypertension. American Journal of Cardiology, 59: 130B (1987.).